Genotoxicity contributes to significant failure in pharmaceutical development at the preclinical stage. 25-30% of drugs are positive for genotoxicity at the candidate selections stage. Rejection of compound due to genotoxicity in preclinical stage can cost millions in wasted development costs. MDS Pharma Services offers rapid and cost-effective early stage testing to identify compounds with genotoxic potential.
|